Novartis India Limited (NOVARTIND.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
62
First IPO Date
October 07, 2020
| Name | Title | Pay | Year Born |
| Vasant Narasimhan | Chief Executive Officer of Novartis | 0 | 1976 |
| Falin Ishwarlal Majmudar | WholeTime Director & Head External Supply Operations | 12.21M | 1968 |
| Shilpa Joshi | Chief Financial Officer & Whole-Time Director | 12.53M | 1969 |
| Chandni Maru | Company Secretary & Compliance Officer | 0 | N/A |
Novartis India Limited, an Indian healthcare enterprise, provides a diverse range of pharmaceutical solutions. Its offerings include branded medications for conditions related to bone and pain management, calcium supplementation, women's health (gynecology), and neurological disorders. Furthermore, the company supplies generic drugs specifically for gynecological issues, anti-tuberculosis treatments, and anti-infective applications. Notable branded products within its portfolio comprise Tegrital and Exelon for central nervous system disorders, Voveran for pain and inflammation relief, and specialized transplantation/immunology drugs like Simulect, Certican, Myfortic, and Sandimmun Neoral. Established in 1947 and headquartered in Mumbai, India, Novartis India Limited operates as a subsidiary of Novartis AG.